Search research articles
Contact Us
Filters
Showing results (51-60 of 65) with videos related to
Page
of 7
Sort By:
Bulletin Du Cancer
|
April 12, 2023
[Treatments for rare ovarian tumors: What's new?]
Coriolan Lebreton, Stanislas Quesada, Marta Bini, et al.
Breast (Edinburgh, Scotland)
|
May 6, 2017
Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB)
Gilles Houvenaeghel, Eric Lambaudie, Monique Cohen, et al.
Breast Cancer Research and Treatment
|
September 22, 2018
Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact
Gilles Houvenaeghel, Alexandre de Nonneville, Monique Cohen, et al.
Annals of Surgical Oncology
|
August 17, 2022
Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers
Fulvio Borella, Stefano Cosma, Domenico Ferraioli, et al.
Cancer Medicine
|
September 21, 2022
The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases
Gilles Houvenaeghel, Alexandre de Nonneville, Nicolas Chopin, et al.
European Journal of Cancer Care
|
September 7, 2020
Impact of multidisciplinary tumour board in the management of ovarian carcinoma in the first-line setting. Exhaustive analysis from the Rhone-Alpes region
Domenico Ferraioli, Olivia Bally, Pierre Meeus, et al.
Gynecologic Oncology
|
April 4, 2020
Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group
Audrey Chevrot, Nicolas Pouget, Anne-Sophie Bats, et al.
Breast Cancer Research and Treatment
|
February 4, 2017
Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study
Alexandre de Nonneville, Anthony Gonçalves, Christophe Zemmour, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 7, 2022
Uptake of Recommendations for Posttreatment Cancer-Related Fatigue Among Breast Cancer Survivors
Antonio Di Meglio, Cecile Charles, Elise Martin, et al.
Journal for Immunotherapy of Cancer
|
August 4, 2025
HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer
Paola Bonaventura, Audrey Page, Olivier Tabone, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 65) with videos related to
Sort By:
Page
of 7
Bulletin Du Cancer
|
April 12, 2023
[Treatments for rare ovarian tumors: What's new?]
Coriolan Lebreton, Stanislas Quesada, Marta Bini, et al.
Breast (Edinburgh, Scotland)
|
May 6, 2017
Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB)
Gilles Houvenaeghel, Eric Lambaudie, Monique Cohen, et al.
Breast Cancer Research and Treatment
|
September 22, 2018
Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact
Gilles Houvenaeghel, Alexandre de Nonneville, Monique Cohen, et al.
Annals of Surgical Oncology
|
August 17, 2022
Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers
Fulvio Borella, Stefano Cosma, Domenico Ferraioli, et al.
Cancer Medicine
|
September 21, 2022
The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases
Gilles Houvenaeghel, Alexandre de Nonneville, Nicolas Chopin, et al.
European Journal of Cancer Care
|
September 7, 2020
Impact of multidisciplinary tumour board in the management of ovarian carcinoma in the first-line setting. Exhaustive analysis from the Rhone-Alpes region
Domenico Ferraioli, Olivia Bally, Pierre Meeus, et al.
Gynecologic Oncology
|
April 4, 2020
Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group
Audrey Chevrot, Nicolas Pouget, Anne-Sophie Bats, et al.
Breast Cancer Research and Treatment
|
February 4, 2017
Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study
Alexandre de Nonneville, Anthony Gonçalves, Christophe Zemmour, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 7, 2022
Uptake of Recommendations for Posttreatment Cancer-Related Fatigue Among Breast Cancer Survivors
Antonio Di Meglio, Cecile Charles, Elise Martin, et al.
Journal for Immunotherapy of Cancer
|
August 4, 2025
HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer
Paola Bonaventura, Audrey Page, Olivier Tabone, et al.
Page
of 7